BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1374 related articles for article (PubMed ID: 8616953)

  • 21. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heart transplantation in females.
    Esmore D; Keogh A; Spratt P; Jones B; Chang V
    J Heart Lung Transplant; 1991; 10(3):335-41. PubMed ID: 1854761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of antilymphocyte induction therapy in liver transplantation.
    Wall WJ
    Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S64-70. PubMed ID: 10431019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
    Guttmann RD; Flemming C
    Clin Transplant; 1997 Jun; 11(3):185-92. PubMed ID: 9193840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunosuppression in live-related donor renal transplantation.
    Iman A; Rao M; Juneja R; Jacob CK
    Natl Med J India; 2001; 14(2):75-80. PubMed ID: 11396322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine.
    Knight RJ; Kerman RH; Podder H; Katz SM; Van Buren CT; Kahan BD
    Transplant Proc; 2005 Mar; 37(2):1280-2. PubMed ID: 15848695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late acute rejection in long-term renal allograft recipients. Diagnostic and predictive value of circulating activated T cells.
    Reinke P; Fietze E; Döcke WD; Kern F; Ewert R; Volk HD
    Transplantation; 1994 Jul; 58(1):35-41. PubMed ID: 7913561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term kinetics of a T-lymphocytes subset in kidney transplant recipients: relationship with posttransplant malignancies.
    Glowacki F; Al Morabiti M; Lionet A; Labalette M; Provot F; Noel C; Hazzan M
    Transplant Proc; 2009 Oct; 41(8):3323-5. PubMed ID: 19857742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum immunoglobulins and IgG subclass levels in adults with chronic sinusitis: evidence for decreased IgG3 levels.
    Armenaka M; Grizzanti J; Rosenstreich DL
    Ann Allergy; 1994 Jun; 72(6):507-14. PubMed ID: 8203794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring.
    Cosimi AB; Wortis HH; Delmonico FL; Russell PS
    Surgery; 1976 Aug; 80(2):155-63. PubMed ID: 781887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High incidence of posttransplant diabetes mellitus in renal transplant recipients on triple-drug immunosuppression.
    Sakhuja V; Sharma UK; Jha V; Minz M; Chugh KS
    Transplant Proc; 1995 Oct; 27(5):2728-30. PubMed ID: 7482892
    [No Abstract]   [Full Text] [Related]  

  • 32. Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation.
    Olivari MT; Jessen ME; Baldwin BJ; Horn VP; Yancy CW; Ring WS; Rosenblatt RL
    J Heart Lung Transplant; 1995; 14(1 Pt 1):127-35. PubMed ID: 7727461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of immunosuppression therapy following heart transplantation: pretransfusion/azathioprine/ATG/prednisone versus cyclosporine/prednisone.
    Barnhart GR; Goldman MH; Hastillo A; Szentpetery S; Wolfgang T; Thompson J; Mohanakumar T; Katz MR; Rider S; Hanrahan J
    J Heart Transplant; 1985; 4(4):381-4. PubMed ID: 3916511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of immunosuppressive therapy on infectious complications in renal transplant recipients.
    Klauser R; Zlabinger GJ; Traindl O; Franz M; Watschinger B; Pohanka E; Kudlacek S; Kovarik J
    Transplant Proc; 1992 Feb; 24(1):292-4. PubMed ID: 1539284
    [No Abstract]   [Full Text] [Related]  

  • 35. Soluble CD30 in renal transplant recipients: is it a good biomarker to predict rejection?
    Azarpira N; Aghdaie MH; Malekpour Z
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):31-6. PubMed ID: 20061689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.
    Soulillou JP; Cantarovich D; Le Mauff B; Giral M; Robillard N; Hourmant M; Hirn M; Jacques Y
    N Engl J Med; 1990 Apr; 322(17):1175-82. PubMed ID: 2157982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD4+/CD8+ lymphocyte patterns in renal transplant recipients receiving chronic methylprednisolone.
    Tornatore KM; Reed K; Venuto RC
    J Med; 1993; 24(2-3):98-112. PubMed ID: 8105017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced incidence of severe infection after heart transplantation with low-intensity immunosuppression.
    Reid KR; Menkis AH; Novick RJ; Pflugfelder PW; Kostuk WJ; Reid J; Whitby JL; Powell AM; McKenzie FN
    J Heart Lung Transplant; 1991; 10(6):894-900. PubMed ID: 1756154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unique antithymocyte serum versus OKT3 for induction immunotherapy after heart transplantation.
    Frist WH; Merrill WH; Eastburn TE; Atkinson JB; Stewart JR; Hammon JW; Bender JW
    J Heart Transplant; 1990; 9(5):489-94. PubMed ID: 2121921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preemptive therapy with gancyclovir for early high-risk CMV infection allows effective treatment with antithymocyte globulin of steroid-resistant rejection after renal transplantation.
    van Son WJ; van den Berg AP; The TH; Tegzess AM
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1436-8. PubMed ID: 8382873
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 69.